NeoGenomics, Inc. announced its fourth-quarter and full-year 2025 results, reporting a consolidated revenue of $190 million for Q4, an 11% increase over the previous year. The net loss for the quarter decreased by 36% to $10 million, and adjusted EBITDA increased by 13% to $13 million. Full-year consolidated revenue reached $727 million, up 10% from 2024, with a full-year net loss of $108 million and adjusted EBITDA of $43 million.

NeoGenomics delivered a strong third quarter in 2025, with total revenue reaching a record $188 million, an increase of 12% year-over-year. This growth was primarily fueled by an 18% expansion in clinical revenue, with NGS revenue notably increasing by 24% and now constituting nearly one-third of clinical revenue. Despite a 53% increase in net loss to $27 million, the company achieved a positive adjusted EBITDA of $12.2 million, although this was a 9% decline from the prior year. The company reaffirmed its full-year guidance for revenue, net loss, and adjusted EBITDA, indicating confidence in its core business and long-term growth initiatives.

NeoGenomics delivered 10% year-over-year revenue growth to $181,000,000 but widened net loss and saw profitability pressures due to impairments and higher operating costs while key clinical volumes and average revenue per test improved. Guidance for full-year 2025 was reduced.

NeoGenomics reported a solid start to 2025, with consolidated revenue increasing 8% year-over-year to $168 million, driven by higher volume. The net loss decreased by 4% to $26 million, and adjusted EBITDA significantly increased by 102% to $7 million, indicating improved operational efficiency.

NeoGenomics saw an 11% increase in revenue to $172 million in Q4 2024, with an adjusted EBITDA of $12 million, up 27%. Net loss widened to $15 million. Gross profit margin improved to 44.9%, while operational expenses increased due to higher compensation and software support fees.

NeoGenomics reported a 10% increase in consolidated revenue, reaching $168 million, and a 305% increase in adjusted EBITDA to $13 million. Clinical Services revenue grew by 14% to $146 million, driven by higher value tests and strategic reimbursement initiatives. The company revised its full-year 2024 adjusted EBITDA guidance to $37-$40 million.

NeoGenomics reported a 12% increase in consolidated revenue to $165 million and a significant rise in adjusted EBITDA to $11 million. The company has raised its full-year revenue and adjusted EBITDA guidance.

NeoGenomics reported a 14% increase in consolidated revenue to $156 million for Q1 2024. Clinical Services revenue increased by 17% to $135 million, while Advanced Diagnostics revenue decreased by 3% to $22 million. The company's adjusted EBITDA was positive at $3 million, a $11 million increase compared to the previous year. Net loss decreased by 12% to $27 million.

NeoGenomics reported a 12% increase in fourth quarter consolidated revenue, reaching $156 million. Clinical Services revenue increased by 20% to $130 million, while Advanced Diagnostics revenue decreased by 17% to $25 million. The company's net loss decreased by 37% to $14 million, and Adjusted EBITDA was positive at $9 million, an increase of $11 million.

NeoGenomics, Inc. announced its third-quarter results, with consolidated revenue increasing by 18% to $152 million. The company achieved positive adjusted EBITDA of $3 million, a 129% increase year-over-year. Due to this strong momentum, the company raised its full-year guidance.

NeoGenomics reported an 18% increase in consolidated revenue, reaching $147 million in the second quarter of 2023. The company's net loss decreased by 31% to $24 million, and adjusted EBITDA improved by 87% to negative $2 million. Both Clinical Services and Advanced Diagnostics segments contributed to the revenue growth.

NeoGenomics reported a strong first quarter with a 17% increase in consolidated revenue, driven by double-digit growth in both Clinical and Pharma Services. The company's strategic initiatives from the second half of 2022 are positively impacting the business, leading to significant operating leverage and an improvement in Adjusted EBITDA.

NeoGenomics reported a 10% increase in fourth-quarter consolidated revenue, reaching $139 million. The company saw improvements in gross margin and adjusted EBITDA. Clinical Services revenue increased by 4% to $108 million, while Pharma Services revenue increased by 41% to $31 million.

NeoGenomics reported a 6% increase in consolidated revenue, reaching $129 million for the third quarter of 2022. Clinical Services revenue increased by 4% to $106 million, while Pharma Services revenue saw an 18% increase to $23 million. The company's net loss for the quarter was $37 million, compared to a net loss of $20 million for the same period in 2021.

NeoGenomics reported a 3% increase in consolidated revenue for the second quarter of 2022, reaching $125 million. Clinical Services revenue increased by 4% to $106 million, while Pharma Services revenue decreased by 4% to $19 million. The company's net loss for the quarter was $35 million, compared to a net income of $76 million in the same period last year.

NeoGenomics reported a 1% increase in consolidated revenue to $117 million for Q1 2022. Clinical Services revenue increased by 2%, while Pharma Services revenue decreased by 4%. The company experienced a net loss of $49 million, compared to a net loss of $22 million in the same period last year, due to increased operating expenses and amortization of acquired technology.

NeoGenomics, Inc. reported fourth quarter consolidated revenue of $126 million, which was flat compared to the fourth quarter of 2020. Excluding COVID-19 PCR testing, consolidated revenue increased year-over-year by 7%. The company's net loss for the quarter was $42 million, compared to net income of $15 million in the fourth quarter of 2020.

NeoGenomics reported a consolidated revenue of $121 million, a decrease of 3% compared to the same period in 2020. However, excluding COVID-19 PCR testing, Clinical Services revenue increased by 11% year-over-year. The company is planning to double its sales team to support RaDaR™.

NeoGenomics reported a 40% increase in consolidated revenue, reaching $122 million in the second quarter of 2021. The company's clinical services revenue grew by 37% to $101 million, while pharma services revenue increased by 55% to $20 million. The company also completed the acquisitions of Trapelo Health and Inivata Limited during the quarter.

NeoGenomics reported a 9% increase in consolidated revenue to $116 million for the first quarter of 2021. The company completed the acquisition of Trapelo Health in April and announced the acquisition of Inivata. However, the company's net loss increased to $22 million, and adjusted EBITDA decreased to $4 million.

NeoGenomics, Inc. reported an 18% increase in consolidated revenue for the fourth quarter of 2020, reaching $126 million. Clinical Services revenue increased by 14% to $107 million, while Pharma Services revenue grew by 43% to $19 million. Net income for the quarter was $15 million, compared to $6 million in the same period of 2019.

NeoGenomics reported a 20% increase in consolidated revenue, reaching $125 million in Q3 2020. The company saw growth in both Clinical Services and Pharma Services, driven by increased test volume and strategic investments in areas such as global Pharma Services, Informatics, and liquid biopsy.

NeoGenomics reported a challenging second quarter due to the global COVID-19 crisis, which reduced both revenue and earnings. However, the company made several strategic moves and investments, including fortifying the balance sheet, investing in Inivata, launching liquid biopsy tests, globalizing Pharma Services, and operationalizing a high-capacity COVID-19 testing laboratory.

NeoGenomics, Inc. reported an 11% increase in consolidated revenue to $106.0 million for the first quarter of 2020. Clinical Services revenue increased by 7.9% to $93.0 million, while Pharma Services revenue grew by 39.3% to $13.0 million. The company experienced a net loss of $7.0 million, compared to a net loss of $2.4 million in the first quarter of 2019.

NeoGenomics reported a strong Q4 2019, with a 40% increase in consolidated revenue to $106.9 million. The company saw growth in both Clinical and Pharma Services, driven by market share gains and strategic investments. Net income increased significantly, and the company issued positive financial guidance for 2020.